- Resource
- BR1DGE
- Management
- Monitoring
- Video
Advancing Models of Care for People with Type 1 Diabetes
Leading T1D experts discuss supportive care pathways, psychosocial support, and new models of care for people at risk of, or diagnosed with, type 1 diabetes.
Learning Objectives
- Understand the importance of pathways that provide education and psychosocial support for people at risk of, or diagnosed with, type 1 diabetes
- Recognize the roles of both clinicians and families in managing type 1 diabetes across all stages
Summary
This video discusses the reframing of type 1 diabetes (T1D) as a progressive, detectable disease and the need to build care pathways that can educate, support, and reduce the risk of diabetic ketoacidosis. Prof Chantal Mathieu emphasizes that early-stage T1D can be identified and managed before clinical diagnosis and symptom onset. Jaivir Pall highlights the role of the wider care team in addressing psychosocial needs, including peer mentors, family members, dietitians, and nurses. Prof Francesco Giorgino calls for new organizational models to identify, follow up, and support people at high risk of T1D, with greater collaboration across specialties.
MAT-GLB-2601300 - 1.0 - 08/2026
Faculty Disclosures
Prof Chantal Mathieu
- Research funding: Medtronic, Imcyse, Novo Nordisk, Sanofi, and ActoBio Therapeutics
- Speaker/Consultant: Sanofi
- Other: Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion, and Vertex
Jaivir Pall
- Speaker/Consultant: Sanofi, AbbVie
- Other: Eli Lilly and Company, Novo Nordisk, Dexcom, Minimed, Boehringer Ingelheim, Roche, Zubi Capital Diabetes-Immune, Fund I, Abvance Therapeutics, Ancilia Biosciences, Viven Therapeutics, Zya Enzymes, Zubi Group, Luna Life Limited, Unison Bio, BioSapien and Harbr Ventures Fund
Prof Francesco Giorgino
- Research funding: Eli Lilly, Roche Diabetes Care
- Speaker/Consultant: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi
- Other: President of European Association for the Study of Diabetes (EASD)/European Foundation for the Study of Diabetes (EFSD), and Vice Chair of the European Diabetes Forum (EUDF)
The Evolving Landscape of Early Detection in T1D
Leading T1D experts discuss scaling up screening programs to support equitable access to early T1D detection, monitoring, and disease-modifying therapies.
Communicating the Benefits of T1D Screening and Early Detection
Experts discuss how to effectively communicate the value of T1D screening and early detection to families, clinicians, and healthcare decision-makers.
Identifying Adult-onset T1D
Leading T1D experts explore how to distinguish adult-onset T1D from T2D and when to consider islet autoantibody testing in adults.